Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?

ABSTRACT: Functional reserve of organs and systems is known to be relevant in predicting immunochemotherapy tolerance. Age and comorbidities, assessed by the cumulative illness rating scale (CIRS), have been used to address chemotherapy intensity. In the ibrutinib era, it is still unclear whether age, CIRS, and Eastern Cooperative Oncology Group performance status (ECOG-PS) retain their predictive role on treatment vulnerability. In this series of 712 patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib outside clinical trials, baseline ECOG-PS and neutropenia resulted as the most accurate predictors of treatment feasibility and outcomes. Age did not independently influence survival and ibrutinib tolerance, indicating that not age per se, but age-related conditions, may affect dru

SUBMITTER: Tedeschi A 

PROVIDER: S-EPMC8714729 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature